Make sure your research teams stay on the cusp of scientific innovation in diabetes therapeutics—expanding beyond even the current GLP-1 marketplace. This Workshop explores the evolution of GLP-1 therapeutics, research into new modalities to treat Diabetes, the future of the GLP-1 market, and innovation in GLP-1 agonists. Each session offers scientific insights that executives at both large and small pharmaceutical firms can use as they evaluate the future business direction of diabetes therapeutics.
Get inside the business of one of the currently most impactful and important drug categories and indications – GLP-1 therapeutics for the treatment of diabetes and obesity. Review the drug class, the scope of the market and what it may still hold in terms of business opportunities. In these sessions, we look ahead into new modalities in development and get some insight into the complexities of the rapidly expanding space of compounded GLP-1s.
We also examine some key hurdles for the development of modalities in this drug class, look further on the horizon of innovation within and beyond the GLP-1 drug class by also discussing issues like patient adherence as well as the role of biomarkers in the discovery of diabetes and obesity treatments.
-
The Mechanics and Evolution of GLP-1 Therapeutics — Jens Juul Holst, M.D., University of Copenhagen
-
Beyond GLP-1: What Does the Market Look Like Today? — Tim Opler, Ph.D., Stifel
-
Structuring Business Development Deals for New Modalities - Katie Hewitt, Ph.D.
-
The Contribution of Glia to GLP-1 Therapeutics: New Drug Targets - Caroline Geisler, Ph.D., University of Kentucky
-
Key Issues in the GLP-1 Compounding Space — Zach Zalewski, Ph.D., USP
-
GLP-1 Challenges and Obstacles of the Future - Jim McGuire, Ph.D.
-
Addressing Patient Adherence: Advances in Drug Delivery — Adam Mendelsohn, Ph.D., Vivani Medical
-
GLP-1-Induced Adverse Events — Jonathan Douros, Ph.D., Indiana Biosciences Research Institute
-
What Does the Future Look Like for Innovation in GLP-1 Agonists? — Richard DiMarchi, Ph.D., Indiana Univer
-
Biomarkers in Advancing Diabetes and Obesity Therapeutics — Annika Carlsson, Ph.D., Mercodia
-
The Contribution of Glia to GLP-1 Therapeutics: New Drug Targets - Caroline Geisler, Ph.D., University of Kentucky
Pricing:
Members: Full Workshop $750 USD
Non-Members: Full Workshop $1100 USD
Course objectives:
- Provide an overview of the product class and the different types of RNA-based therapeutics that have been developed
- Review the overall manufacturing process approaches and associated control strategies
- Discuss key raw material considerations and challenges
- Review conjugation options and strategies
- Consider regulatory approaches, both in terms of licensure pathways and product quality/manufacturing considerations
- Discuss challenges associated with product complexity and gaps in existing regulatory guidance
- Discuss phase-appropriate analytical and product-characterization approaches
- Review approaches to specification-setting for key product quality attributes
Stats Snax discusses basic statistical concepts that apply to the pharmaceutical industry using examples from CMC development areas. Designed for non-statisticians, you will learn foundational concepts that CMC statisticians encounter in their daily interactions with clients.
If you have ever wondered, “What is a p-value?” or “How is expiry determined?” – This series is for you!
Learning Objectives:
- Foundational statistical concepts
- How the topic can be used in daily pharmaceutical operations
- Proper application of statistical concepts, and common misapplication (as appropriate)
